# Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia

> **NCT07352800** · PHASE2 · RECRUITING · sponsor: **Aplagon Oy** · enrollment: 42 (estimated)

## Conditions studied

- Peripheral Arterial Occlusive Disease
- Chronic Limb-Threatening Ischemia

## Interventions

- **DRUG:** APAC - dose level 0.50 mg/kg,
- **OTHER:** Unfractionated heparin (UFH)
- **DRUG:** APAC dose level 1: 0.25 mg/kg,
- **OTHER:** Vehicle (sterile saline, NaCL 0.9%)
- **DRUG:** APAC dose level 2: 0.50 mg/kg,
- **DRUG:** APAC (single periprocedural dose)
- **DRUG:** APAC

## Key facts

- **NCT ID:** NCT07352800
- **Lead sponsor:** Aplagon Oy
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-29
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07352800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07352800, "Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT07352800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*